Tag Archives: Chakrabarty

Chromadex v. Elysium Health – It’s Only Natural!

Posted on February 24, 2023 by Warren Woessner

On February 13, 2023, a Fed. Cir. panel of Judges Prost, Chen and Stoll (Prost writing) held, in Appeal no. 2022-1116, that the asserted claims 1-3 of U.S. Patent No. 8,197, 807 are directed to unpatentable subject matter, namely to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment

Senate Subcommittee on IP Feels our PAIN

Posted on June 6, 2019 by Warren Woessner

In lengthy hearings conducted by the Senate Subcommittee on Intellectual Property (of the Committee on the Judiciary) on June 4th and 5th (Parts I and II; Part III will be held on June 11th), the Subcommittee, chaired by Senators Tillis … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Bipartisan “Draft Bill” to Amend ss. 100, 101 and 112 Released for Comment

Posted on May 24, 2019 by Warren Woessner

On Wednesday, Senators Tillis and Coons, along with Reps. Collins, Johnson and Stivers released a draft, bipartisan bill to amend ss.100 and 101 to void the “judicial exceptions” to patent eligibility. Section 112(f) was also amended to tighten up the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment

Ex parte Ren-Hie Xu – Are Cultured Mammalian Cells Natural Products?

Posted on March 27, 2019 by Warren Woessner

The Examiner in Appeal no. 2017-003416 (Mar. 1, 2019) had rejected this claim as directed to a natural product: “18. An in vitro culture comprising a substantially pure, replenishable population of synchronous primate trophoblast cells, wherein the synchronous primate trophoblast … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment